Brooks-LaSure said the inclusion of semaglutide may help people "to see how important it was for Medicare to get to negotiate prescription drugs." The Biden administration late last year proposed ...

Close to 2.3 million seniors in Medicare are using the semaglutide medications, branded as Ozempic, Rybelsus and Wegovy by Novo Nordisk. Medicare says that the drug added up to more than $14 ...

Federal officials are targeting the blockbuster drugs as part of their ongoing initiative to lower drug costs.

Medicare’s next drug price negotiations will treat Novo Nordisk’s semaglutide as a single product, regardless of whether the metabolic disease medicine is used to treat diabetes or heart risk ...

Novo Nordisk's CEO is not worried about blockbuster semaglutide drugs being added to Medicare drug pricing negotiations this ...

Drugs to treat cancer and type 2 diabetes are among those selected by CMS for the second cycle of Medicare Part D price negotiations. Negotiated prices from the second cycle will take effect in 2027.

Rybelsus (semaglutide) is a brand-name prescription medication that ... If a person has an Original Medicare plan and Part D, they will pay a separate monthly premium for Part D in addition to their ...

Novo Nordisk’s NVO shares lost 5.3% on Friday after Medicare issued a press release selecting the company’s popular semaglutide medicines as one of the 15 additional drugs covered under ...

The CMS listed Ozempic, Rybelsus and Wegovy — all forms of semaglutide — at the top of the list of drugs for which Medicare will the negotiate the price of in 2025. The list price for a one ...

People who stayed on a 7.2 milligram weekly dose of semaglutide lost around 20% of their body weight over 72 weeks.